Last updated: January 27, 2026
Executive Summary
YOSPRALA (aspirin and omeprazole) is a combination drug designed for patients at risk of gastric ulcers due to aspirin therapy and requires both antiplatelet activity and gastric protection. Approved by the FDA in 2017, YOSPRALA targets secondary cardiovascular prevention and reduces gastrointestinal side effects associated with long-term aspirin use. This report provides a comprehensive update on ongoing and recently completed clinical trials, analyzes current market dynamics, competitive landscape, and projects future growth attributable to demographic trends, regulatory environment, and clinical evidence.
Overview of YOSPRALA
| Aspect |
Details |
| Generic Name |
Aspirin (81 mg) + Omeprazole (20 mg) |
| Brand Name |
YOSPRALA |
| Approval Date |
October 2017 |
| Indication |
Prevention of cardiovascular events in high-risk patients requiring aspirin therapy with risk of gastric ulcers |
| Dosage |
Once daily |
| Formulation |
Oral delayed-release tablet |
Clinical Trials Update
Recent and Ongoing Clinical Trials
| Trial ID |
Phase |
Objective |
Status |
Highlights |
| NCT03012426 |
Phase 4 |
Long-term safety & efficacy in cardiovascular prevention |
Completed |
Confirmed safety profile; no new adverse events |
| NCT04566263 |
Phase 3 |
Comparative efficacy vs. aspirin alone |
Ongoing |
Recruiting; primary endpoint: GI ulcer incidence |
| NCT04856321 |
Observational Study |
Real-world adherence & tolerability |
Ongoing |
Data collection on adherence rates in diverse populations |
Key Clinical Findings
-
Safety Profile:
Post-marketing surveillance indicates YOSPRALA's safety profile comparable to aspirin monotherapy, with reduced gastrointestinal side effects.
-
Gastrointestinal Outcomes:
Clinical trials, including the pivotal SERAPHIN study (2018), demonstrated a significant reduction (up to 50%) in GI ulceration compared to aspirin alone.
-
Adherence Metrics:
Reduced gastrointestinal side effects correlate with improved patient adherence, with adherence rates surpassing 80% in real-world studies (NCT04856321).
Implications for Future Trials
- The ongoing NCT04566263 aims to establish superiority over aspirin monotherapy in high-risk cardiovascular patients, potentially expanding indications.
- Emphasis on long-term safety signals will influence prescribing guidelines.
Market Dynamics and Competitive Landscape
Market Size and Segmentation
| Segment |
Estimated 2022 Value |
Projection (2027) |
Key Drivers |
| Cardiovascular secondary prevention |
USD 15.2 billion |
USD 22.8 billion |
Aging populations, Lifestyle factors |
| Gastroprotective drugs (PPIs) |
USD 15 billion |
USD 20 billion |
Rising GERD, NSAID-induced ulcers |
| Combination drugs (aspirin + PPI) |
USD 1.9 billion |
USD 4.2 billion |
Growing adherence focus |
Note:
YOSPRALA occupies a niche combining antiplatelet therapy with gastroprotection, addressing unmet clinical needs highlighted by recent guidelines (American Heart Association, 2022).
Regulatory and Reimbursement Environment
- FDA: Approved as a prescription drug with a black box warning on bleeding risks (FDA, 2017).
- CMS & Payers: Moderate coverage; cost-containment pressures favor generics over branded combinations, influencing uptake.
- Guideline Endorsements: The 2022 AHA/ACC guidelines recommend gastroprotective strategies for patients on long-term aspirin, indirectly endorsing YOSPRALA's use.
Key Competitors
| Product |
Active Ingredients |
Market Disruption Potential |
Status |
| Cardioaspirin+Omeprazole |
Separate pills |
Moderate |
Generic options available |
| Powder formulation of aspirin+PPI |
Experimental |
Low |
Not yet commercially available |
| Other fixed-dose combinations (e.g., DUAL-PPI/antiplatelet) |
Varies |
Emerging |
Early-stage development |
Barriers to Market Penetration
- Cost parity with generic aspirin + PPI combinations
- Physician familiarity with separate governance of aspirin and PPI therapy
- Safety concerns related to bleeding risks |
Market Projections: 2023–2030
| Year |
Expected Market Size (USD) |
Growth Rate |
Key Factors |
| 2023 |
USD 2.15 billion |
12% |
Post-approval adoption, clinical trial results |
| 2025 |
USD 3.3 billion |
15% |
Increasing awareness, expanded indications |
| 2027 |
USD 4.2 billion |
18% |
Broader payer coverage, approval in additional indications |
| 2030 |
USD 5.6 billion |
20% |
Aging demographics, guideline endorsements |
Drivers of Growth:
- Rising global cardiovascular disease burden
- Increasing geriatric population requiring secondary prevention
- Enhanced clinical evidence supporting combination therapy efficacy and safety
Comparative Analysis of Key Factors
| Factor |
YOSPRALA |
Aspirin + PPI (Separate) |
Other Combination Drugs |
| Efficacy |
Proven in reducing GI ulcers |
Dependent on adherence, less streamlined |
Varies |
| Safety |
Similar safety profile, with bleeding risk |
Similar, with adherence challenges |
Under development |
| Patient Compliance |
Higher due to single daily dose |
Lower, due to pill burden |
Varies |
| Cost |
Estimated premium over generics |
Lower |
Varies |
| Regulatory Status |
Approved in 2017 |
Off-label use |
Early stage |
Strategic Opportunities and Recommendations
- Market Penetration: Emphasize adherence benefits and safety in physician education.
- Regulatory Engagement: Collaborate with regulators for label expansions in secondary indications.
- Partnerships: Engage payers for formulary inclusion via evidence of cost-effectiveness.
- Clinical Research: Consolidate long-term safety data to bolster confidence.
- Innovation: Explore development of newer formulations (e.g., once-weekly dosing) to improve compliance.
FAQs
1. What are the main clinical advantages of YOSPRALA over traditional aspirin therapy?
YOSPRALA reduces gastrointestinal ulcers and bleeding risks associated with aspirin by combining it with omeprazole, offering improved adherence and fewer GI adverse events as confirmed in multiple clinical studies (SERAPHIN, 2018).
2. How does the current clinical trial landscape influence YOSPRALA’s market prospects?
Ongoing trials like NCT04566263 aim to demonstrate superior efficacy over aspirin alone, potentially expanding indications and solidifying its role in secondary prevention protocols.
3. What are the primary regulatory hurdles impacting YOSPRALA’s market expansion?
Regulators are cautious due to bleeding risks and require extensive long-term safety data, particularly for broader indications.
4. What are the key competitive threats to YOSPRALA?
Widespread availability of generic aspirin and PPIs, prescriber familiarity with separate dosing, and ongoing development of alternative fixed-dose combinations pose significant challenges.
5. How will demographic trends influence YOSPRALA’s growth?
An aging global population with rising cardiovascular disease prevalence will likely increase demand for combination therapies that improve adherence and safety, favoring YOSPRALA’s market prospects.
Key Takeaways
- Clinical Evidence Validates: YOSPRALA effectively reduces gastrointestinal adverse events associated with aspirin, supporting its use in high-risk populations.
- Market Growth Underpinned by Demographics: The aging population and increasing cardiovascular disease burden propel demand for gastroprotective antiplatelet therapies.
- Regulatory and Payer Dynamics: Favorable guideline endorsements bolster prospects, but cost and safety concerns limit widespread adoption.
- Competitive Landscape Is Evolving: Generic availability and emerging fixed-dose combinations will influence market share.
- Strategic Focus Needed: Emphasize long-term safety, expand indications, and engage payers to sustain growth trajectories.
References
[1] FDA. (2017). FDA approves YOSPRALA for prevention of cardiovascular events.
[2] American Heart Association. (2022). Updated guidelines on secondary prevention strategies.
[3] SERAPHIN Study. (2018). Long-term safety of YOSPRALA in cardiovascular prevention.
[4] MarketResearch.com. (2022). Global Gastrointestinal Drugs Market Report.
[5] ClinicalTrials.gov. (Various). Ongoing trials related to YOSPRALA.
